Navigation Links
Researchers discover how cancer 'invisibility cloak' works
Date:10/28/2013

Researchers at National Jewish Health have discovered how a lipid secreted by cancer tumors prevents the immune system from mounting an immune response against it. When lysophosphatidic acid (LPA) binds to killer T cells, it acts almost like an "invisibility cloak," preventing T cells from recognizing and attacking nascent tumors.

"In recent years, several therapeutic medicines have been developed that spur a person's own immune system to fight cancer," said Raul Torres, PhD, professor of immunology at National Jewish Health, and senior author on the paper, published in the October issue of Cancer Immunology Research. "Our findings suggest new targets and strategies for enlisting the immune system's help in fighting cancer."

Scientists believe the human immune system recognizes and destroys many cancerous cells before they develop into dangerous tumors. However, tumors also employ strategies to evade detection by the immune system.

Scientists have known that LPA is secreted by many types of cancer cells, appears to promote the growth and spread of tumor cells, and that immune cells known as CD-8 "killer" T cells have several receptors for LPA. Killer T cells can destroy cancer cells when activated against them.

In the new paper, researchers led by Dr. Torres showed that LPA keeps T cells inactivated even after they have "seen" a target, or antigen, on a cancer cell that would normally trigger an immune response. They identified the LPA5 receptor as the specific receptor responsible for inhibiting the immune response. In cell cultures and in mice LPA prevented signaling within cells, the appearance of molecules associated with T-cell activation, and proliferation of the T cells. When they transferred T cells lacking the LPA5 receptor into mice with cancer, tumor growth essentially halted.

"Knowing specifically how LPA inhibits the immune response suggests several strategies for harnessing the immune system's natural ability to fight cancer," said Dr. Torres.


'/>"/>

Contact: William Allstetter
allstetterw@njhealth.org
303-398-1002
National Jewish Health
Source:Eurekalert

Related biology news :

1. Oregon researchers say supplement cuts muscle loss in knee replacements
2. BUSM researchers identify molecule that could aid lung cancer detection, treatment
3. Researchers identify gene variant that raises risk for colorectal cancer from eating processed meat
4. Researchers show how plants tell the time
5. Berkeley Lab researchers get a detailed look at a DNA repair protein in action
6. Researchers capture images of open channel that moves proteins across cell membranes
7. UAlberta medical researchers discover potential new treatment for colitis
8. Older siblings cells can be passed from female dogs to their puppies in the womb, MU researchers find
9. Nitrogen fertilizer remains in soils and leaks towards groundwater for decades, researchers find
10. Researchers discover innate virus-killing power in mammals
11. CNIO researchers delve into the behavior of cohesins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... Jan. 5, 2017  Delta ID Inc., a leader ... technology for automotive at CES® 2017. Delta ID has ... to demonstrate the use of iris scanning as a ... the driver in a car, and as a way ... experience. Delta ID and Gentex will demonstrate ...
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
(Date:12/19/2016)... , España y TORONTO , 19 de diciembre ... Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un ... en varios tipos de tumor en 2017, con múltiples sitios previstos ... ... clase con objetivo en el factor inhibidor de leucemia (LIF), una ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... ... ... The two newest companies to join the University City Science Center’s Port ... The Wistar Institute, and Sanguis, launched by a trio of students from the University ... is developing a treatment for a chronic viral infection and its associated diseases, with ...
(Date:1/20/2017)... , Jan. 20, 2017 Ginkgo ... of Gen9, a pioneer in the synthesis and ... unique expertise in assembling pathway-length synthetic DNA into ... and capacity in the construction of new organism ... industries. "Gen9 was founded to significantly ...
(Date:1/20/2017)... MA (PRWEB) , ... January ... ... leader in Less Exposure Surgery (LES®) Technologies, announced today the next evolution ... PedFuse Pedicle Screw System platform). In contrast to the competition, SpineFrontier is ...
Breaking Biology Technology: